Publications
Publications
Show Results For
- All HBS Web
(707)
- Faculty Publications (416)
- 2019
- Working Paper
Thinking Outside the Box (12): The Benefits of Increased Transparency in Employer-Sponsored Health Insurance for the 180 Million Insured
By: Regina E. Herzlinger and Barak D. Richman
Economists have long noted that the tax exclusion of employer-sponsored insurance (ESI) caused workers to purchase health plans that differ in price and other characteristics from those they would otherwise choose for themselves. We explore the short-term and long-term... View Details
- 26 Nov 2019
- Interview
Who Killed Healthcare? Dr. Regina Herzlinger Knows Who's Guilty
- October 10, 2019
- Article
The Case for the Public Option Over Medicare for All
By: Regina E. Herzlinger and Richard Boxer
How can the United States better control its health care costs and quality and still achieve universal coverage? The strongest choice is not Medicare for All, which would eliminate private insurance; it’s the public option, which would allow people to choose from... View Details
- Article
Europe's Alternative to Medicare for All: Swiss and Dutch Private Insurance Provide Better Coverage Than Canada's Single-Payer System
By: Regina E. Herzlinger and Bacchus Barua
An analysis of Canada’s single-payer healthcare system shows the dangers of the proposed Medicare for All model. In fact, the Canadian healthcare system is costly and drives poor outcomes when compared to objective performance measures. Alternatively, the Swiss and... View Details
- May 2018 (Revised October 2020)
- Supplement
La Ribera Health Department (B): Epilogue
By: Regina E. Herzlinger, Emer Moloney and Daniela Beyersdorfer
The La Ribera case studies depict an innovative low cost/high quality privately financed hospital model struggling to achieve alignment with the Six Factors. It is reimbursed by the public sector in a Spanish environment whose Consumers, Structure, and Public Policy... View Details
- February 2018
- Case
Health Savings Accounts: Enabling Consumer Participation
By: Regina E. Herzlinger and James Wallace
Health savings accounts (HSAs), a creation of the 2003 Medicare Modernization Act, had become an integral part of the drive toward consumer-driven health care. Coupled with high-deductible health plans, HSAs allowed consumers to directly control a significant part of... View Details
- August 2017
- Teaching Note
Health Stop (A) and (B)
Teaching Note for HBS Nos. 185-084 and 196-051. View Details
- May 2017 (Revised February 2021)
- Case
Prevent Senior: A New Paradigm for Growth in the Health Care Sector?
By: Regina E. Herzlinger, Ana Maria Malik and Priscilla Zogbi
- April 2017
- Teaching Note
CV Ingenuity (A) and (B)
Teaching Note for HBS Nos. 315-045 and 315-087. View Details
- February 2017 (Revised February 2021)
- Case
Hebrew SeniorLife: Next Steps
By: Regina E. Herzlinger, Carin-Isabel Knoop and Olivia Hull
The CEO of Hebrew SeniorLife is contemplating how to scale his highly successful but asset-intensive continuing care retirement community for elders. Among the strategies he is considering is an expansion to China; virtual web-based care; providing continuing care in... View Details
- January 2017 (Revised March 2021)
- Case
Fitbit
By: Regina E. Herzlinger, Christine Snively and Sarah Mehta
In 2019, Fitbit lost its leadership in the wearable sensor market to Apple and to cheaper alternatives.
Why did it lose its market position?
How will the proposed acquisition affect it and Google? View Details
Why did it lose its market position?
How will the proposed acquisition affect it and Google? View Details
- September 2015 (Revised February 2023)
- Case
Emdeon's Acquisition of Change Healthcare: Innovating Transparency Solutions for Health Care Consumers
By: Regina E. Herzlinger, Jeet Guram and Aanchal Raj
Case describes acquisition of Change Healthcare, which provides health care cost and quality information, by Emdeon, a health information exchange, and discusses health care transparency. Emdeon is a billion-dollar company that has grown through acquisitions; at its... View Details
- May 2015
- Case
Acıbadem Healthcare Group
By: Regina E. Herzlinger, Esel Çekin, Natalie Kindred and Gamze Yucaoglu
Acıbadem Healthcare Group is Turkey's only premium nationwide hospital network. This case focuses on Acıbadem’s potential expansion strategy after it was acquired by International Healthcare Holdings Berhad (IHH) in 2011, the world's second-largest publicly listed... View Details
- May 2015
- Supplement
OdontoPrev (B)
- March 2015 (Revised November 2017)
- Case
Bonitas
By: Regina E. Herzlinger and Natalie Kindred
Bonitas, a South African medical scheme (i.e., health insurer), must navigate highly restrictive regulations that make it difficult for Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas... View Details
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
- Article
Market-Based Solutions to Antitrust Threats—The Rejection of the Partners Settlement
By: Regina E. Herzlinger, Barak D. Richman and Kevin A. Schulman
- February 2015
- Supplement
MedCath Corporation (C)
By: Regina E. Herzlinger, Kevin Schulman and F. Fallon Upke
MedCath is a horizontally integrated chain of heart hospitals that partners with local cardiologists. It claims that its focus leads to better and cheaper results than those of an everything-for-everybody general hospital. Community hospitals generally vehemently... View Details